CLX
Heads-up: USD JOLTS Job Openings is due in 16 h (high impact). The outlook can shift noticeably around it.
- Clorox's first-quarter fiscal 2027 update put input cost inflation at the centre of the outlook, with management launching improvement measures to offset it.
- The shares have had a hard year: a September review cited a 29.65% decline, thinner free cash flow and elevated liabilities, feeding questions about the dividend.
- Combining CloroxPro with GOJO to grow B2B healthcare is the clearest structural positive, though its payoff is likely to be gradual.
- Bearish items are more recent and higher-impact than the bullish one, so near-term sentiment leans negative while the overall view stays balanced.
News situation · 2 items / 30 D
2 of 2 straight from the issuer or regulator
Clorox sits in a holding pattern. The latest quarterly update, covering the first quarter of fiscal 2027, put persistent input cost inflation at the centre of the story, with management flagging it as the main drag on the year ahead while launching performance improvement measures to counter it.
Read full analysis
That is a cautious message rather than a dire one, and it lands on top of a rough stretch for the shares: a dividend-risk piece in September pointed to a 29.65% fall in the stock, thinner free cash flow and elevated liabilities, and a separate note flagged 27.7% underperformance over the past year. Against that, the combination of CloroxPro with GOJO to build a larger presence in B2B healthcare is a genuine structural positive, though its benefit will arrive gradually. A co-branded marketing event with Kingsford was immaterial. There are no technical signals on the page today, so the picture rests entirely on this fundamental mix, and that mix is finely balanced: two bearish items, one bullish, two neutral, with moderate impact and confidence. The bearish pieces are more recent and carry more weight, which is why near-term sentiment leans negative even as the overall verdict stays neutral.
Supporting factors
- Performance improvement strategies launched alongside the fiscal 2027 first-quarter results, aimed at offsetting cost pressure.
- The CloroxPro and GOJO combination, which widens the company's reach into B2B healthcare.
- Any management commentary on pricing actions or cost mitigation that shows margins stabilising.
Risks and what to watch
- Persistent input cost inflation, which management named as the primary headwind for fiscal 2027.
- Dividend sustainability questions after thinner free cash flow and elevated liabilities were flagged in September.
- The stock's weak run, with a 29.65% decline and 27.7% underperformance over the past year, can feed further investor skepticism.
- A heavy run of US data in the coming days, including jobs figures and ISM surveys, sets the macro backdrop for the shares.
What is driving Clorox shares at the moment?
Two forces are pulling in opposite directions. On one side, the first-quarter fiscal 2027 results made clear that input cost inflation remains the dominant headwind, and that follows a September review pointing to a 29.65% share decline, thinner free cash flow and elevated liabilities. On the other, the tie-up of CloroxPro with GOJO opens a larger B2B healthcare opportunity. Because the negative items are more recent and carry more weight, near-term sentiment leans negative, but the balance of evidence is not strong enough to call the overall picture bearish.
What did the latest quarterly results say?
The first-quarter fiscal 2027 release focused on operational improvement. Management explicitly identified ongoing input cost pressures as the primary headwind for the fiscal year and pointed to newly initiated performance improvement strategies as the response. There was no dramatic surprise in the message, which is why it registered as neutral rather than negative, but it did confirm that margin pressure is expected to persist rather than fade quickly.
Is the dividend under threat?
A September analysis raised the question rather than answering it. It highlighted a 29.65% fall in the share price alongside thinner free cash flow and elevated liabilities, which are the ingredients that put a payout under scrutiny. Nothing in the more recent quarterly update resolved that concern, and management's emphasis on cost pressure keeps it live. Free cash flow improvement is the thing to watch.
What would change the neutral view?
Clear evidence that cost pressure is easing would shift the balance positive, whether through pricing actions, the performance improvement programme or a better margin picture in the next update. Progress in integrating CloroxPro and GOJO into a meaningful B2B healthcare business would help over time. On the other side, further free cash flow deterioration or a weaker demand picture would tilt the balance negative.
Both worlds over time
Technical and news signals of the last 90 days on one timeline.
CLX fundamental outlook?
From news analysis — different time windows than the trading horizons above
Over the next 1-7 days, CLX is likely to remain under pressure as investors digest the Q1 FY2027 results and the ongoing input cost narrative. Watch for any management commentary on cost mitigation or pricing actions; a break below recent lows could trigger further selling, while a stabilization above the 52-week low might offer a technical bounce.
In the next 1-4 weeks, the stock will likely trade on broader market sentiment and any updates on the B2B integration. The dividend risk highlighted in September remains a lingering concern; if free cash flow does not improve, the stock could face additional downside. Conversely, successful execution of the CloroxPro/GOJO combination could provide a modest positive catalyst.
Over the next 1-3 months, CLX's trajectory will hinge on its ability to manage input cost inflation and execute its performance improvement strategies. The structural shift toward B2B healthcare is a positive long-term driver, but the company must demonstrate margin recovery to restore investor confidence. If cost pressures persist, the stock may continue to underperform; however, successful cost actions could lead to a re-rating.
Economic data for CLX
Full calendarRecently released
- TodayUSDISM Manufacturing Prices Paid●●●Forecast 80.7Previous 77.9
- TodayUSDISM Manufacturing PMI●●●Forecast 54.7Previous 54.5
Coming up
- TomorrowUSDJOLTS Job Openings●●●Forecast 6.779MPrevious 7.079Min 16h
- November 4, 2026USDADP Nonfarm Employment Change●●●Forecast 64KPrevious 90Kin 1 day
- November 4, 2026USDISM Non-Manufacturing Prices Paid●●●Forecast 69.5Previous 74.0in 1 day
- November 4, 2026USDISM Non-Manufacturing PMI●●●Forecast 55.2Previous 54.9in 1 day
- November 4, 2026USDEIA Crude Oil Stocks Change●●●in 1 day
- November 5, 2026USDInitial Jobless Claims●●●in 2 days
- November 6, 2026USDNonfarm Payrolls●●●Forecast 55KPrevious 29Kin 3 days
- November 6, 2026USDUnemployment Rate●●●Forecast 4.2%Previous 4.2%in 3 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
What is being reported about CLX
📝 Overview Generated automatically?
CLX has been the subject of 5 signals across 5 articles in the last 365 days. Sentiment skews Bearish (40%).
Breakdown: 1 bullish, 2 bearish, 2 neutral. AI confidence averages 62% across all signals.
Most-cited catalysts: Initiation of fiscal year 2027 performance improvement strategies (1×), Q1 FY2027 financial results release (1×). Most-cited risk factors: Persistent input cost inflation impacting margins (1×), Operational challenges in navigating macroeconomic headwinds (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.